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Cryptococcus neoformans and C. gattii, the predominant etiological agents of cryptococ-
cosis, can cause life-threatening infections of the central nervous system in immunocom-
promised and immunocompetent individuals. Cryptococcal meningoencephalitis is the
most common disseminated fungal infection in AIDS patients, and C. neoformans remains
the third most common invasive fungal infection among organ transplant recipients. Cur-
rent anti-fungal drug therapies are oftentimes rendered ineffective due to drug toxicity,
the emergence of drug resistant organisms, and/or the inability of the host’s immune
defenses to assist in eradication of the yeast. Therefore, there remains an urgent need for
the development of immune-based therapies and/or vaccines to combat cryptococcosis.
Studies in animal models have demonstrated the efficacy of various vaccination strategies
and immune therapies to induce protection against cryptococcosis. This review will sum-
marize the lessons learned from animal models supporting the feasibility of developing
immunotherapeutics and vaccines to prevent cryptococcosis.
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INTRODUCTION
Cryptococcus neoformans and C. gattii, the etiological agents of
cryptococcosis, are encapsulated fungal pathogens that cause fun-
gal pneumonia and life-threatening infections of the central ner-
vous system (CNS) (Mitchell and Perfect, 1995). Cryptococcal
meningoencephalitis remains the most common disseminated
fungal infection in AIDS patients (Powderly, 1993). Global esti-
mates suggest that one million cases of cryptococcal meningitis
due predominantly to C. neoformans occur each year resulting in
approximately 620,000 deaths (Park et al., 2009). C. gattii primar-
ily causes life-threatening fungal meningitis and infections of the
lung and skin in otherwise healthy individuals (Jarvis and Harri-
son, 2008). The geographical distribution of C. gattii was believed
to be limited to tropical and subtropical climates such as Australia,
New Zealand, and Southeast Asia (Kwon-Chung and Bennett,
1984). However, C. gattii infections began to occur within animal
and human populations on Vancouver Island, British Columbia,
Canada, a temperate climate. Subsequently, C. gattii disseminated
onto the mainland of British Columbia and proceeded throughout
the Pacific Northwest of the United States (Datta et al., 2009a,b;
Centers for Disease Control and Prevention, 2010; Galanis and
Macdougall, 2010).
The administration of highly active antiretroviral therapy
(HAART) has resulted in a decrease in the number of cases of
AIDS-related cryptococcosis in developed countries, but in devel-
oping countries where HAART is not readily available, Cryptococ-
cus is still a major problem (Dromer et al., 2004). Those who are
successfully treated for AIDS-associated cryptococcal meningitis
oftentimes require life-long anti-fungal therapy due to a high
relapse rate (Bozzette et al., 1991; Vibhagool et al., 2003).C. neofor-
mans also remains the third most common invasive fungal infec-
tion among organ transplant recipients (Husain et al., 2001; Singh
et al., 2005; Pappas et al., 2010). Studies have shown that 2.8%
of organ transplant recipients can develop cryptococcal infections
resulting in an overall estimated death rate of 42% (Husain et al.,
2001). Also, cryptococcosis accounted for 8% of the invasive fun-
gal diseases in solid organ transplant recipients in the Transplant
Associated Infection Surveillance Network database from March
2001 to March 2006 (Pappas et al., 2010). The acute mortality rate
is between 10 and 25% in medically advanced countries (Pow-
derly, 1993), and at least one third of patients with cryptococcal
meningitis who receive appropriate therapy will undergo myco-
logic and/or clinical failure (Van Der Horst et al., 1997; Saag et al.,
2000). Thus, there remains an urgent need for therapies and/or
vaccines to combat cryptococcosis.
The current clinical picture of cryptococcosis suggests that
immunosuppressed patients or individuals predicted to be at an
exceptionally high risk for developing cryptococcosis are likely
targets for vaccination to prevent the development of crypto-
coccal disease. Additional target populations for vaccination as
a prophylactic measure include immune competent persons in
high exposure areas as highlighted by the recent C. gattii out-
break in Vancouver Island, British Columbia, Canada, or those
at high risk for exposure to HIV. Animal models of cryptococ-
cosis have been important tools for elucidating the mechanisms
of protection and for testing the efficacy of various antibody
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or antigen-based vaccine candidates. This review will focus on
the lessons learned from animal models of cryptococcal disease
that support efforts toward developing immunological therapies
and/or vaccines against cryptococcosis.
HOST RESPONSE TO CRYPTOCOCCUS
The consensus is that cell-mediated immunity (CMI) primarily
by Th1-type CD4+ T cells directs the protective host immune
response against C. neoformans (Huffnagle et al., 1991; Casadevall,
1995; Zhang et al., 2009), whereas a Th2-type immune response is
considered detrimental to the host (Arora et al., 2005; Jain et al.,
2009). A Th1-type response is characterized by the production of
interleukin (IL)-2, IL-12, interferon-gamma (IFN-γ), and tumor
necrosis factor-alpha (TNF-α) (Cherwinski et al., 1987). These
cytokines induce granuloma formation in the lung to wall off the
yeast and are responsible for initiating delayed-type hypersensi-
tivity (DTH) reactions that lead to enhanced uptake, killing by
neutrophils and dendritic cells, and the induction of classically
activated macrophages (Cher and Mosmann, 1987; Zhang et al.,
2009; Arora et al., 2011). A Th2-type response is characterized by
the production of IL-4, IL-5, IL-9, IL-10, and IL-13 (Cherwinski
et al., 1987), and is associated with eosinophilic inflammation and
dissemination of cryptococci to the CNS (Huffnagle et al., 1994;
Olszewski et al., 2001; Muller et al., 2007). A Th17-type response
consisting of IL-17, IL-21, and IL-22 (reviewed in Onishi and
Gaffen, 2010) has been suggested to be important in protection
against C. neoformans, however, it seems to play a secondary role
to the Th1-type response (Kleinschek et al., 2010). When a Th17-
type response is blocked, there is no effect on survival of mice with
experimental pulmonary C. neoformans infection (Wozniak et al.,
2011a).
The predominant studies evaluating host immune responses to
cryptococcal infections have been performed using C. neoformans
as the model organism. However, several studies now suggest that
the mechanism for mediating protection against C. neoformans
infections differs from that which induces protection against C.
gattii. Experimental studies suggest that C. gattii may thrive in
immune competent hosts by suppressing host immune responses
(Dong and Murphy, 1995; Wright et al., 2002; Cheng et al., 2009;
Kronstad et al., 2011). C. gattii strain R265, the predominant iso-
late of the Vancouver Island outbreak, has been shown to be more
suppressive in mice compared to those infected with C. neofor-
mans. C. gattii infected mice had decreased neutrophil recruitment
and decreased pro-inflammatory cytokine production (Dong and
Murphy, 1995; Wright et al., 2002; Cheng et al., 2009).
While the patient population that historically develops crypto-
coccal infections includes individuals with defects in CMI, patients
with defects in antibody-mediated immunity (AMI) such as
hypogammaglobulinemia and hyper-IgM syndrome also have an
increased probability of developing cryptococcosis (Gupta et al.,
1987; Iseki et al., 1994; Tabone et al., 1994; Casadevall, 1995; Anta-
chopoulos et al., 2007). The role of AMI in cryptococcal infections
is complicated in that antibodies can be protective, non-protective,
or can exacerbate the infection (Casadevall, 1995; Mukherjee
et al., 1995a,b; Yuan et al., 1998). Antibody protection against
cryptococcosis is dependent on the antibody isotype, concentra-
tion, and specificity (reviewed in Casadevall, 1995). Comparisons
of variable-region-identical mAbs to the glucuronoxylomannan
(GXM) component of the C. neoformans polysaccharide capsule
of the murine IgG1, IgG2a, IgG2b, and IgG3 isotypes have con-
sistently shown that all IgG isotypes, except IgG3 are protective
against C. neoformans infection in mice (Yuan et al., 1995, 1998;
Nussbaum et al., 1996). Resistance to disease may depend upon the
proportion of protective anti-cryptococcal antibodies produced
during infection. However, the efficacy of anti-cryptococcal anti-
bodies of a protective isotype can be lost if induced or passively
administered in excess creating a prozone-like effect (Taborda and
Casadevall, 2001; Taborda et al., 2003). Other major determinants
of the effectiveness of antibody isotype against C. neoformans
infection include mouse genetics (Rivera and Casadevall, 2005;
Zaragoza et al., 2007), T cell function (Yuan et al., 1997), and the
presence of Th1- and Th2-related cytokines (Beenhouwer et al.,
2001). Despite what we know from animal studies concerning
protective antibody isotypes, the efficacy of various immunoglob-
ulin isotypes against C. neoformans may vary between humans
and mice (Beenhouwer et al., 2007) necessitating some caution
in trying to translate findings in animal models to the clinic.
Nevertheless, anti-cryptococcal antibodies can act as opsonins,
participate in antibody-dependent cellular cytotoxicity, augment
Th1-type polarization, and help to eliminate immunosuppressive
polysaccharide antigen from serum and tissues. They also inhibit
cryptococcal biofilm formation, alter lipid metabolism resulting in
increased sensitivity to anti-fungal drugs, have direct anti-fungal
activity, and modulate the immune response to prevent host dam-
age (Martinez and Casadevall, 2005; Casadevall and Pirofski, 2007;
Mcclelland et al., 2010; Brena et al., 2011). The role of antibodies
in the host defense against fungal infection remains controver-
sial; however, some recent studies continue to show a protective
role of antibodies against cryptococcosis. For example, naturally
occurring IgM (nIgM) is essential for the prevention of crypto-
coccosis in mice (Subramaniam et al., 2010). Cryptococcal disease
is more severe in mice lacking serum IgM and in sIgM knockout
mice. Experimental pulmonary C. neoformans infection of sIgM
knockout mice results in increased mortality and higher blood
and brain fungal burden compared to that observed in wild-type
infected mice. While it is generally agreed that the protective host
immune response toC. neoformans is dependent on inducing pro-
tective CMI, AMI certainly contributes in the protection against
cryptococcosis.
CRYPTOCOCCAL PROTEIN TARGETS
Significant efforts have been made towards identification of
cryptococcal antigens that induce Cryptococcus-specific Th1-type
immune responses. This effort is based on the predominant role
for CMI responses to mediate protection against C. neoformans
infections. Protein antigens can induce T-dependent immune
responses and thus be highly immunogenic. Additionally, pro-
teins are biochemically defined, thus allowing for the production
of large quantities of recombinant proteins. There is also no fear of
protein “reversion” that could possibly occur using an attenuated
strain to induce immunity. Immunization of mice with C. neo-
formans culture filtrate antigen (CneF), which contains secreted
proteins as well as cell wall-associated proteins, resulted in the
stimulation of DTH responses (Murphy et al., 1988). Fractionation
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of CneF revealed its mannoprotein (MP) fraction as the pri-
mary antigenic component responsible for DTH and T-dependent
immune responses in mice (Murphy et al., 1988; Levitz and Specht,
2006). Mice given two immunizations of purified cryptococcal MP
(MP98) experienced prolonged survival and had reduced CFUs in
the organs when compared to the control mice receiving adjuvant
alone (Mansour et al., 2002). Cryptococcal MP induced Th1-type
responses in immunized mice upon infection with C. neoformans
(Mansour et al., 2002). Four protective MP, one being a chitin
deacetylase (MP98) (Levitz et al., 2001), one of unknown function
(MP88) (Huang et al., 2002), and an additional two, MP84 and
MP115 (Biondo et al., 2005) have been found.
In addition to the MP found in the cell wall, other potential
targets include the heat shock protein (hsp) family (Kakeya et al.,
1997; Nooney et al., 2005), fungal glucosylceramide (Rodrigues
et al., 2007), and melanin (Rosas et al., 2001). MAbs to melanin
have been shown to prolong the survival of and reduce fungal
burden in lethally infected mice and reduce the growth rate of
the fungus in vitro (Rosas et al., 2001). In the hsp family, hsp70
has been found to be highly immunogenic (Kakeya et al., 1997).
Mycograb, a recombinant antibody targeting an epitope within
the hsp90 of Candida albicans that is conserved in Cryptococ-
cus, leads to enhanced fungicidal activity when combined with
amphotericin B treatment of infected mice (Nooney et al., 2005).
Targeting antigens common to multiple fungal species such as hsps
or melanin may serve to extend protection to multiple disparate
fungal pathogens.
CYTOKINE IMMUNOTHERAPIES
Adaptive immunity against cryptococcosis is orchestrated via
cytokine/chemokine production by Th1-type CD4+cells. Conse-
quently, the historic objective of most immune-based therapies
has been to skew the non-protective immune responses toward a
protective Th1-type immune response. For example, IL-2 given
along with a CD40 agonist antibody significantly prolonged the
survival of C. neoformans-systemically infected mice (Zhou et al.,
2006, 2007). In addition, mice depleted of CD4+ T cells were pro-
tected when stimulated with CD40 and IL-2 compared to depleted
mice without these stimulations. This model also showed signifi-
cant reduction of fungal burden in the organs and increased levels
of IFN-γ and TNF-α (Zhou et al., 2006, 2007). Furthermore,
mice treated with recombinant TNF-α experienced significantly
prolonged survival times compared to non-treated control mice
(Kawakami et al., 1996a). Additionally, treatment of mice with a
TNF-α-expressing adenoviral vector after experimental challenge
of C. neoformans resulted in a significant decrease in fungal bur-
den, an increase in IFN-γ levels, and an increase in infiltration
of macrophages and neutrophils (Milam et al., 2007). Treatment
with IL-12 also led to significant increases in survival of mice
with experimental cryptococcosis, but the timing of the treatment
is important. Treating mice with IL-12 for 7 days post infection
resulted in 90% survival, but delaying IL-12 treatment until day
7 post infection negated the effect of the IL-12, and the mice had
similar survival rates compared to the untreated mice (Kawakami
et al., 1996c). Administering IL-23, a cytokine necessary for the
proliferation and stabilization of the Th17-type cells (reviewed in
Onishi and Gaffen, 2010), significantly extended the survival of
intraperitoneally infected mice (Kleinschek et al., 2010). However,
when compared to their positive control group that received IL-12
and showed 100% survival at day 100, it was concluded that IL-23
may play only a limited role in the protection againstC. neoformans
(Kleinschek et al., 2010). Treating mice with IL-2 and anti-CD40,
TNF-α, or IL-12 led to an increase in IFN-γ levels (Kawakami
et al., 1996c; Zhou et al., 2006; Milam et al., 2007). Giving mice
daily injections of IFN-γ prolonged their survival and reduced the
fungal burden in the lungs and the brain (Kawakami et al., 1996b).
Studies in humans indicated that the cytokine profile at the
site of infection determines the rate of clearance. Patients with
higher IFN-γ at the site of infection had a faster rate of clearance
compared to those with lower levels (Siddiqui et al., 2005), sug-
gesting that the microenvironment at the site infection is more
important than the macroenvironment. Considering this study,
a highly virulent strain of C. neoformans, H99, was modified to
produce murine IFN-γ. Mice given an experimental pulmonary
infection with the IFN-γ producing C. neoformans strain, desig-
nated H99γ,were capable of completely resolving the infection and
showed 100% protection upon re-challenge with wild-type cryp-
tococci (Wormley et al., 2007). This protection was shown to be T
cell dependent and B cell independent (Wozniak et al., 2009). T cell
knock out (KO) mice succumbed to an experimental pulmonary
infection with H99γ whereas B cell KO mice survived and showed
100% protection upon challenge with the wild-typeC. neoformans
strain H99 (Wozniak et al., 2009). Mice immunized with the H99γ
strain and then depleted of either CD4+ or CD8+ T cells prior to
and during subsequent challenge with wild-type C. neoformans,
remained 100% protected (Wozniak et al., 2009). Remarkably,
when the same experiment was performed with depletion of both
CD4+ and CD8+ T cells during the challenge with wild-type cryp-
tococci, there was still 80% survival (Wozniak et al., 2011b). These
results suggest that if immune competent individuals are immu-
nized against C. neoformans and then become T cell deficient they
may still be protected. This system also produced high amounts
of IL-17A, but when IL-17A deficient or IL-17A receptor KO mice
were immunized with the H99γ strain there was no difference
in protection compared to the wild-type mice (Hardison et al.,
2010; Wozniak et al., 2011a). Thus, IL-17A may contribute to, but
ultimately be dispensable for, protection against C. neoformans
infection.
Cytokine treatment has also shown promising results when
administered along with conventional anti-fungal drugs. In a
systemic infection model, treating mice with IL-12 along with
fluconazole significantly lowered the fungal burden in the brain
compared to mice treated with fluconazole alone (Clemons et al.,
1994). Administering IFN-γ along with amphotericin B during
a lethal systemic infection model significantly lowered the fungal
burden in the brain compared to amphotericin alone (Lutz et al.,
2000). In a sub-lethal systemic infection model amphotericin B
with IFN-γ led to complete clearance of the infection (Lutz et al.,
2000). Fluconazole and IFN-γ significantly lowered the fungal bur-
den in both the lethal and sub-lethal systemic infection models
but failed to completely resolve the infection in any of the models
(Lutz et al., 2000). Cytokine treatment may be necessary consid-
ering the immune suppressed status of the typical cryptococcosis
patient. However, the possible induction of C. neoformans-related
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immune reconstitution inflammatory syndrome (IRIS) which is
the induction of over-exuberant pro-inflammatory responses fol-
lowing the resolution of immune suppression necessitates caution
when proceeding with such approaches.
ANTIBODY-MEDIATED IMMUNOTHERAPIES AND ANTIBODY
VACCINES
One of the main virulence factors of Cryptococcus is the polysac-
charide capsule that is comprised primarily of the polysaccharides
GXM and galactoxylomannan (GalXM) and to a much lesser
extent,<1%, MP (Zaragoza et al., 2009). Cryptococcal polysaccha-
rides such as GXM have profound suppressive effects on immune
responses and elicit little to no antibody responses making it an
unlikely choice as an antigen (reviewed in Zaragoza et al., 2009).
GXM can bleb off the fungus and direct immune responses away
from infection, while GXM and GalXM both can non-specifically
diminish lymphocyte proliferation and induce apoptosis (Yauch
et al., 2006; Cutler et al., 2007; Chow and Casadevall, 2011; Vec-
chiarelli et al., 2011). However, an entirely plausible strategy to
induce protection against cryptococcosis may be to develop anti-
bodies against specific capsular components. Mouse models have
been utilized to investigate the efficacy of cryptococcal conju-
gate vaccines in which GXM or GalXM has been conjugated to
protein carriers (Casadevall et al., 1992, 1998; Devi, 1996; Chow
and Casadevall, 2011). GXM conjugated to the tetanus toxoid
resulted in anti-GXM protective antibody responses and antibod-
ies specific for GXM which help protect against cryptococcosis
(Casadevall et al., 1992, 1998; Devi, 1996). Two GalXM conju-
gates where tested and found to be useful in generating high titers
of anti-GalXM antibodies in the serum, but the responses were
not protective (Chow and Casadevall, 2011). Casadevall devel-
oped an antibody to the capsule, 18B7, which was found to bind
to all serotypes, enhance phagocytosis, and help with the clearance
of the blebs of polysaccharide released by the fungus (Casadevall,
1995). Recently, MAb 18B7 has been conjugated to the therapeutic
radioisotopes 188Rhenium or 213Bismuth (Dadachova et al., 2003;
Bryan et al., 2010) and studied as a potential radioimmunother-
apy (RIT) against C. neoformans. Administration of radiolabeled
MAb 18B7 to lethally infected mice resulted in prolonged survival,
reduced organ fungal burden, and was a more effective therapy
compared to mice treated with amphotericin B alone.
A potential strategy to circumvent the immunosuppressant
effects of GXM and GalXM may be to focus on specific epi-
topes within the polysaccharides that elicit protective antibody
responses. An approach using small peptides that mimic defined
GXM or GalXM epitopes may elicit protective antibody responses
where using total polysaccharides has immunosuppressive effects.
Peptides which are able to induce antibodies that are capable of
binding to the native antigen when administered as immuno-
gens are termed mimotopes. A peptide mimetic (P13) of GXM
was developed that is recognized by human anti-GXM antibod-
ies (Zhang et al., 1997). Vaccination with P13-protein conjugates
in mice elicited an antibody response to GXM (Zhang et al.,
1997). Additionally, mice immunized with the conjugates expe-
rienced prolonged survival after an otherwise lethal C. neoformans
challenge compared to controls (Fleuridor et al., 2001) or fol-
lowing establishment of a chronic infection (Datta et al., 2008).
Immunization with P13-protein conjugates also prolonged sur-
vival in mice transgenic for human immunoglobulin loci (Fleuri-
dor et al., 2001) and passive immunization with serum from
P13-conjugate vaccinated mice to naïve mice conferred partial
protection to a lethal cryptococcal challenge (Maitta et al., 2004;
Datta et al., 2008). Nonetheless, the therapeutic efficacy of con-
jugate vaccines containing a peptide mimotope of GXM appears
to depend on the genetic background of the host and the carrier
protein employed (Datta et al., 2008). Conjugation of P13 to key-
hole limpet marine mollusk (KLH) elicited an anti-GXM response
to non-protective epitopes possibly due to the generation of non-
protective antibodies against an epitope within the carrier protein
that is cross-reactive to GXM (May et al., 2003).
Development of antibodies targeting essential components
within the fungal cell wall may be an additional method of
antibody-mediated protection against cryptococcosis. Treatment
with an anti-β-glucan antibody, MAb 2G8, which targets β(1,3)
glucans of the brown algae, Laminaria digitata, was shown to
inhibit capsule formation and growth of C. neoformans in vitro
and mediate a significant reduction in fungal burden in mice
given an experimental systemic cryptococcal infection (Rachini
et al., 2007). Also, passive immunization with MAbs against
melanin or glucosylceramide prolonged the survival of mice given
a lethal infection with C. neoformans (Rosas et al., 2001; Rodrigues
et al., 2007). Again, targeting fungal antigens that are common
among multiple fungal pathogens is an appealing strategy toward
generating cross-protection using one immune-therapy and/or
vaccine.
CONCLUSION
The need for novel treatments to combat cryptococcosis is
expected to rise. This is due to an increasing population of immune
compromised patients, a high relapse rate, and increased per-
centage of patients predicted to experience mycologic and/or
clinical failure. Animal models of cryptococcosis have been
important tools for elucidating the mechanisms of protection
against cryptococcosis and for testing the efficacy of various
antibody or antigen-based vaccine candidates against cryptococ-
cal infection. Overall, animal models have provided a means
for studying strategies for modulating T helper responses and
evaluating antibodies and radioimmunotherapies. They have
also proved useful in developing approaches for inducing cell
responses using peptide mimotopes and specific cryptococcal
antigens. Perhaps a shift in approach from defining targets for
anti-fungal drug development toward devising immune ther-
apies and/or vaccines that enhance host anti-fungal immune
responses is a direction requiring more focus. Such studies
will concentrate more on the host and less on the pathogen.
Still, Cryptococcus is a disease in which the host and pathogen
are intimately intertwined. Consequently, animal models will
surely be required to understand the relationship and devise
plausible treatments and/or vaccines to prevent cryptococcal
infections.
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